Cargando…

Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study

An extrafine formulation of the long-acting muscarinic antagonist glycopyrronium bromide (GB) is in development for chronic obstructive pulmonary disease (COPD), in combination with beclometasone dipropionate and formoterol fumarate – a “fixed triple”. This two-part study was randomized, double blin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Dave, Scuri, Mario, Collarini, Sara, Vezzoli, Stefano, Mariotti, Fabrizia, Muraro, Annamaria, Acerbi, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511020/ https://www.ncbi.nlm.nih.gov/pubmed/28744115 http://dx.doi.org/10.2147/COPD.S137659

Ejemplares similares

Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)
por: Beeh, Kai M, et al.
Publicado: (2018)

Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma
por: Kuna, Piotr, et al.
Publicado: (2022)

Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide
por: Singh, Dave, et al.
Publicado: (2017)

A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug–Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993
por: Mariotti, Fabrizia, et al.
Publicado: (2016)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study
por: Usmani, Omar S., et al.
Publicado: (2022)

The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN)
por: Skloot, Gwen S., et al.
Publicado: (2023)

Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease
por: Leaker, Brian R., et al.
Publicado: (2019)

Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial
por: O'Connor, Brian J, et al.
Publicado: (2011)

The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone/formoterol/glycopyrronium on gas trapping in COPD
por: Dean, James, et al.
Publicado: (2020)

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
por: Muro, Shigeo, et al.
Publicado: (2019)

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation
por: Singh, Dave, et al.
Publicado: (2019)

The efficacy of extrafine beclomethasone dipropionate–formoterol fumarate in COPD patients who are not “frequent exacerbators”: a post hoc analysis of the FORWARD study
por: Singh, Dave, et al.
Publicado: (2017)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids
por: Paggiaro, Pierluigi, et al.
Publicado: (2016)

Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma
por: Chapman, Kenneth R., et al.
Publicado: (2021)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
por: D’Urzo, Anthony
Publicado: (2013)

Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study
por: Voorham, Jaco, et al.
Publicado: (2020)

A novel model-based approach for dose determination of glycopyrronium bromide in COPD
por: Arievich, Helen, et al.
Publicado: (2012)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
por: Mantero, Marco, et al.
Publicado: (2018)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
por: Ridolo, Erminia, et al.
Publicado: (2019)

Effectiveness of glycopyrronium bromide in the treatment of small airway dysfunction: A retrospective study
por: Petrone, Albino, et al.
Publicado: (2022)

Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life
por: Rossi, Andrea, et al.
Publicado: (2015)

Predictors of clinical response to extrafine and non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma
por: Gafar, Fajri, et al.
Publicado: (2018)

Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
por: Prakash, Anoop, et al.
Publicado: (2015)

A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use
por: Chiu, Michael H., et al.
Publicado: (2016)

Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine
por: Mohan, V., et al.
Publicado: (2021)

Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial
por: Beeh, Kai-Michael, et al.
Publicado: (2021)

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
por: Buhl, Roland, et al.
Publicado: (2018)

Real-World Safety and Efficacy of Glycopyrronium Bromide in Japanese Patients with COPD: A 52-Week Post-Marketing Surveillance
por: Kato, Chihiro, et al.
Publicado: (2022)

Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells
por: Cazzola, Mario, et al.
Publicado: (2016)

Extrafine inhaled corticosteroid therapy in the control of asthma
por: Ivancsó, István, et al.
Publicado: (2013)

Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease
por: Singh, Dave, et al.
Publicado: (2016)

Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis
por: Barjaktarevic, Igor Z, et al.
Publicado: (2019)

Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
por: Singh, Dave, et al.
Publicado: (2014)

Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors
por: Liu, Haiying, et al.
Publicado: (2022)

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
por: Singh, Dave, et al.
Publicado: (2020)

Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
por: Ulrik, Charlotte Suppli
Publicado: (2014)

The future of bronchodilation: looking for new classes of bronchodilators
por: Cazzola, Mario, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r5jo2d9j311r4367sun86qjtjg